Active, not recruitingPhase 2NCT05125809
Setrusumab vs Placebo for Osteogenesis Imperfecta
Studying Osteogenesis imperfecta
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ultragenyx Pharmaceutical Inc
- Principal Investigator
- Ultragenyx Medical DirectorUltragenyx Pharmaceutical Inc
- Intervention
- Setrusumab(biological)
- Enrollment
- 183 enrolled
- Eligibility
- 5-25 years · All sexes
- Timeline
- 2022 – 2025
Study locations (20)
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Shriners Hospital for Children - Northern California, Sacramento, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Connecticut Children's Medical Center, Hartford, Connecticut, United States
- Yale New Haven Hospital, New Haven, Connecticut, United States
- Nemours/ Alfred i. duPoint Hospital for Children, Wilmington, Delaware, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- University of South Florida, Tampa, Florida, United States
- Shriners Hospitals for Children - Chicago, Chicago, Illinois, United States
- Indiana University Hospital, Indianapolis, Indiana, United States
- Kennedy Krieger Institute, Baltimore, Maryland, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Children's Hospital and Medical Center, Omaha, Nebraska, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05125809 on ClinicalTrials.govOther trials for Osteogenesis imperfecta
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07366086Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis ImperfectaAmgen
- RECRUITINGPHASE2NCT07062588Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)Angitia Incorporated Limited
- RECRUITINGNANCT07412782REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)Meyer Children's Hospital IRCCS
- RECRUITINGNANCT07478224An Interventional Study to Evaluate the Impact of Blood Flow Restriction Training on Muscle, Bone, and Quality of Life in Adults With Osteogenesis Imperfecta Type IUniversity Hospital, Ghent
- RECRUITINGNCT07287241Prospective Observational Cohort Study of Cardiac Structure and Function in Children and Adults With Osteogenesis ImperfectaIstituto Ortopedico Rizzoli
- ACTIVE NOT RECRUITINGPHASE3NCT06636071Setrusumab in Pediatric Japanese Subjects With Osteogenesis ImperfectaUltragenyx Pharmaceutical Inc
- RECRUITINGPHASE3NCT05972551Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis ImperfectaAmgen
- RECRUITINGNANCT05927389Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Osteogenesis ImperfectaUniversity Hospital, Toulouse